{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:18:58Z","timestamp":1736399938338,"version":"3.32.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748"],"award-info":[{"award-number":["P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Palmar-plantar erythrodysesthesia (PPE) is a slowly developing cutaneous reaction commonly experienced by patients treated with fluoropyrimidines. While erythrodysesthesia normally presents in a palmar-plantar distribution, it can also present with genital involvement, but this presentation is likely underreported and incorrectly attributed to an acute reaction from radiation therapy. This article aims to define erythrodysesthesia of the penis and scrotum as a rare but significant side effect of capecitabine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We identified five cases of moderate to severe penis and scrotal erythrodysesthesia over a 2-year period at a large tertiary cancer center, representing an estimated incidence of 3.6% among male patients with rectal cancer who were treated with fluoropyrimidine-based chemoradiation within our institution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Improved understanding of erythrodysesthesia involving the penis and scrotum can facilitate early identification and treatment of symptoms, and possibly prevent the discontinuation or delay of cancer treatment in patients treated with capecitabine and similar drugs. These clinical advances would improve and prolong patient quality of life during cancer treatment and prevent complications that result in hospitalization.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00384-024-04647-2","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T04:01:55Z","timestamp":1716436915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series"],"prefix":"10.1007","volume":"39","author":[{"given":"Angela","family":"Adames","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Roth","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard B.","family":"Saltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Garcia-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Zinovoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vonetta","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha","family":"Reyngold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Crane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Joshua","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cuaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"McCann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Romesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"4647_CR1","unstructured":"NCCN (NCCN) (2023) NCCN clinical practice guidelines in oncology rectal cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf. Accessed 18 Oct 2023"},{"issue":"18","key":"4647_CR2","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","volume":"32","author":"MJ O\u2019Connell","year":"2014","unstructured":"O\u2019Connell MJ, Colangelo LH, Beart RW et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32(18):1927\u20131934. https:\/\/doi.org\/10.1200\/JCO.2013.53.7753","journal-title":"J Clin Oncol"},{"issue":"17","key":"4647_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa040694","journal-title":"N Engl J Med"},{"issue":"8","key":"4647_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1056\/NEJM199408253310803","volume":"331","author":"MJ O\u2019Connell","year":"1994","unstructured":"O\u2019Connell MJ, Martenson JA, Wieand HS et al (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331(8):502\u2013507. https:\/\/doi.org\/10.1056\/NEJM199408253310803","journal-title":"N Engl J Med"},{"key":"4647_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv248","author":"CJ Allegra","year":"2015","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ et al (2015) Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv248","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4647_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14740338.2011.546342","volume":"10","author":"MW Saif","year":"2011","unstructured":"Saif MW (2011) Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 10(2):159\u2013169. https:\/\/doi.org\/10.1517\/14740338.2011.546342","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"4647_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","volume":"11","author":"JD Webster-Gandy","year":"2007","unstructured":"Webster-Gandy JD, How C, Harrold K (2007) Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11(3):238\u2013246. https:\/\/doi.org\/10.1016\/j.ejon.2006.10.004","journal-title":"Eur J Oncol Nurs"},{"issue":"5","key":"4647_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3816\/CCC.2007.n.008","volume":"6","author":"CM Sapp","year":"2007","unstructured":"Sapp CM, DeSimone P (2007) Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer 6(5):382\u2013385. https:\/\/doi.org\/10.3816\/CCC.2007.n.008","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"4647_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1080\/02841860802698858","volume":"48","author":"YJ Lee","year":"2009","unstructured":"Lee YJ, Lee HJ, Jeong KC, Kang JG, Lee SH, Kim YT (2009) An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis. Acta Oncol 48(4):636\u2013637. https:\/\/doi.org\/10.1080\/02841860802698858","journal-title":"Acta Oncol"},{"issue":"9","key":"4647_CR10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archdermatol.2011.257","volume":"147","author":"B Fleta-Asin","year":"2011","unstructured":"Fleta-Asin B, Alcantara-Gonzalez J, Alonso-Castro L, Truchuelo-Diez M, Jaen-Olasolo P (2011) Genital erythrodysesthesia as a severe manifestation of capecitabine therapy: a report of 3 cases. Arch Dermatol 147(9):1123\u20131124. https:\/\/doi.org\/10.1001\/archdermatol.2011.257","journal-title":"Arch Dermatol"},{"issue":"6","key":"4647_CR11","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1111\/jdv.14090","volume":"31","author":"S Ljubojevic Hadzavdic","year":"2017","unstructured":"Ljubojevic Hadzavdic S, Stulhofer Buzina D, Murtezani I, Skerlev M (2017) Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine. J Eur Acad Dermatol Venereol 31(6):e304\u2013e306. https:\/\/doi.org\/10.1111\/jdv.14090","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"4647_CR12","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.7759\/cureus.3704","volume":"10","author":"HP Hu","year":"2018","unstructured":"Hu HP, Corkum MT, Perera F (2018) Palmar-plantar erythrodysesthesia with genital involvement secondary to capecitabine chemoradiotherapy: a case report. Cureus 10(12):e3704. https:\/\/doi.org\/10.7759\/cureus.3704","journal-title":"Cureus"},{"issue":"4","key":"4647_CR13","doi-asserted-by":"publisher","first-page":"e7724","DOI":"10.7759\/cureus.7724","volume":"12","author":"J Dricken","year":"2020","unstructured":"Dricken J, Pettke E, Griffin JA, Li HY, Mehta V (2020) Scrotal and penile erythrodysesthesia associated with neoadjuvant capecitabine chemoradiation. Cureus 12(4):e7724. https:\/\/doi.org\/10.7759\/cureus.7724","journal-title":"Cureus"},{"issue":"1","key":"4647_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40880-019-0399-z","volume":"39","author":"S Lin","year":"2019","unstructured":"Lin S, Yue J, Guan X et al (2019) Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer Commun (London) 39(1):57. https:\/\/doi.org\/10.1186\/s40880-019-0399-z","journal-title":"Cancer Commun (London)"},{"issue":"6","key":"4647_CR15","first-page":"2307","volume":"29","author":"A Martschick","year":"2009","unstructured":"Martschick A, Sehouli J, Patzelt A et al (2009) The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 29(6):2307\u20132313","journal-title":"Anticancer Res"},{"issue":"26","key":"4647_CR16","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696\u20132704. https:\/\/doi.org\/10.1056\/NEJMoa043116","journal-title":"N Engl J Med"},{"issue":"13","key":"4647_CR17","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378(13):1177\u20131188. https:\/\/doi.org\/10.1056\/NEJMoa1713709","journal-title":"N Engl J Med"},{"key":"4647_CR18","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (2017)"},{"issue":"4","key":"4647_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71(4):787\u2013794. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4647_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.seminoncol.2016.02.018","volume":"43","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Levy LL, Choi JN (2016) Cutaneous manifestations of nontargeted and targeted chemotherapies. Semiars in Oncology 43(3):419\u2013425. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.02.018","journal-title":"Semiars in Oncology"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04647-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-024-04647-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04647-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:59:48Z","timestamp":1736326788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-024-04647-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4647"],"URL":"https:\/\/doi.org\/10.1007\/s00384-024-04647-2","relation":{},"ISSN":["1432-1262"],"issn-type":[{"type":"electronic","value":"1432-1262"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"8 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective analysis was approved by the institutional review board with a waiver of informed consent. Medical records were reviewed for patients with rectal adenocarcinoma who were treated with fluoropyrimidine-based chemoradiation from January 2021 through December 2023 at our institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written consent for publication of their clinical details and\/or clinical images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Angela Adames serves on the Oncology Nursing Certification Corporation (ONCC) test development committee for the Oncology Certified Nurses (OCN<sup>\u00ae<\/sup>) examination, is this committee\u2019s current chair, and receives travel and lodging support from ONCC outside of the submitted work.\u00a0Leonard B. Saltz served as a consultant for Genor Biopharma Holdings Ltd. and Optimal Cancer Care Alliance (OCCA) and received research funding from Taiho Pharmaceutical outside of the submitted work.\u00a0Julio Garcia-Aguilar has provided professional services to Ethicon and Intuitive Surgical Inc. outside of the submitted work.\u00a0Andrea Cercek has received grants and contracts from GlaxoSmithKline and Seagen Inc. and has received honoraria from Bayer, GI Therapeutics, GlaxoSmithKline, Janssen Biotech, Merck, Pfizer Pharmaceuticals LLC, Roche, Amgen, Abbivie, and Seagen Inc. outside the submitted work.\u00a0Christopher Crane serves as a consultant for TriSalus Life Siences. He has received research funding from Elekta outside of the submitted work.\u00a0J. Joshua Smith received travel support for fellow education from Intuitive Surgical. He also served as a clinical advisor for Guardant Health as a clinical advisor for Foundation Medicine and as a consultant and speaker for Johnson and Johnson. He serves as a clinical advisor and consultant for GSK outside of the submitted work.\u00a0Abraham Wu has provided consulting services to CivaTech Oncology, Inc., MORE Health, Inc., Nanovi A\/S, and Simphotek, Inc. outside of the submitted work.\u00a0Alina Markova has provided consulting services to ADC Therapeutics, Alira Health, AstraZeneca, Protagonist Therapeutics, OnQuality, and Janssen. She has also received research funding from Amryt Pharma, AstraZeneca, Incyte Corporation, Kintara Therapeutics, Novocure, and royalties from UptoDate outside of the submitted work.\u00a0Paul B. Romesser received research funding and serves as a consultant for EMD Serono, receives research funding from XRAD Therapeutics, is a consultant for Faeth Therapeutics, is a consultant for Natera, and is a volunteer on the advisory board for the HPV Alliance and Anal Cancer Foundation non-profit organizations outside of the submitted work.\u00a0All other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}